Ginkgo Results Presentation Deck

Continuing to execute well on our plans in the second quarter of 2022 Active Programs 46 5 10 13 9 9 Q2 2021 73 2 26 22 13 10 Q2 2022 CRONOS GROUP • Announced the achievement of the third target productivity milestone, THCV, in our partnership to produce eight cultured cannabinoids Progress on Key Metrics Government Pharma & Biotech Food & Agriculture Industrial & Environmental Consumer & Technology +13 Diverse New Programs: 元 VO novo nordisk SUMITOMO CHEMICAL Strong Biosecurity Performance: $247 million Year-to-date Biosecurity Revenue zymergen Ⓡ Announced a definitive agreement under which Ginkgo will acquire Zymergen Recently awarded contract to continue CDC's Traveler-based SARS-CoV-2 Genomic Surveillance Program • The acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform evo Company Highlights JOYN BIO BAYER E Signed definitive agreement to acquire Bayer's 175,000-square-foot Biologics R&D center • Ginkgo will also enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs 3x+ Y-O-Y Revenue Growth $44 $22 Strong Financial Health $22 Q2 2021 bitome better tools, faster science. • Acquired assets from Bitome are expected to support accelerated product development timelines across Ginkgo's portfolio of cell programs through its real-time metabolite monitoring technology $145 $100 $44 Q2 2022 Biosecurity ($M) Foundry ($M) -$1.4 billion in cash provides ample runway • Appointed Dr. Kathy Hopinkah Hannan to Board of Directors. Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist 7 Property of Ginkgo Bioworks Q2 2022 UPDATE & BUSINESS REVIEW

View entire presentation